In addition to documented weight reduction, the cardiovascular protective effects of SGLT2 inhibitors include reduction in blood pressure [59] and reduced risk of both new heart failure and of worsening existing heart failure in patients with reduced or preserved ejection fraction [51,52,53,60,61,62]. The gene discussed is SLC5A2; the disease is heart failure.